Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial

BACKGROUND: The De-ESCALaTE HPV trial confirmed the dominance of cisplatin over cetuximab for tumour control in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here, we present the analysis of health-related quality of life (HRQoL), resource use, and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Jones, David A., Mistry, Pankaj, Dalby, Matthew, Fulton-Lieuw, Tessa, Kong, Anthony H., Dunn, Janet, Mehanna, Hisham M., Gray, Alastair M.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Science Ltd 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947474/
https://ncbi.nlm.nih.gov/pubmed/31794928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.10.025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados